Form 4: Theravance Biopharma Director Acquires Shares and Options

Director Eran Broshy reports acquisition of shares and options in Theravance Biopharma.

Summary

• On May 19, 2025, Eran Broshy, a director of Theravance Biopharma, acquired 10,649 ordinary shares at $0 and disposed of 91,204 ordinary shares.
• Broshy also acquired 24,258 share options with an exercise price of $9.39, exercisable from May 19, 2025, and expiring on May 18, 2035.
• The options vest in installments over time, with the remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders, provided the optionee remains in continuous service on such date.
• Following these transactions, Broshy directly owns 24,258 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without expressing an opinion on the company's prospects. The acquisition of shares and options is offset by the disposal of shares.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Negatives

• The disposal of 91,204 ordinary shares by the director could be seen as a negative signal.

Risks

• The vesting schedule of the options is tied to continued service, which could create retention risks.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests an expectation of continued service from the director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's sentiment and expectations for the company's performance.

Comparison to Industry Standards

• Director share ownership is common across publicly traded companies, and the size of the holdings and option grants are generally benchmarked against peer companies of similar size and industry.
• Option vesting schedules are also standard practice, often tied to continued employment and performance milestones.

Stakeholder Impact

• Shareholders may interpret the director's transactions as a signal of confidence or concern.
• Employees may view the option grants as an incentive for continued service.

Next Steps

• Monitor future Form 4 filings to track changes in insider ownership.
• Observe the director's continued service to assess the vesting of the options.

Key Dates

Keywords

Theravance Biopharma, Director, Eran Broshy, Share Options, Ordinary Shares, Acquisition, Disposition, Form 4, Beneficial Ownership